The children’s vaccine “Baby-Hib” against hemophilus influenzae type b, developed by scientists from the Federal Medical-Biological Agency of Russia (FMBA), is at the final stage of registration, said first deputy head of the agency Tatyana Yakovleva. As previously reported, it is planned to launch production of the drug at the facilities of the Saint Petersburg Scientific Research Institute of Vaccines and Serums of the FMBA of Russia in 2024.
In addition, speaking about the latest achievements of the FMBA, she added that the anti-influenza vaccine “Flu-M” has successfully passed the WHO prequalification procedure. “And for the Flu-M Tetra vaccine, the indications for age have been expanded from 6 months to 17 years in Russia, and registration has also been obtained in three Latin American countries,” Yakovleva emphasized.
